Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer

Pas encore traduit Pas encore traduit
Auteurs
Catégorie Primary study
Registry of Trialsclinicaltrials.gov
Year 2006

This article is not included in any systematic review

This article is part of the following publication threads:
Loading references information
This study will evaluate the effects of nadroparin on survival and disease progression in patients with hormone-refractory prostate cancer (HRPC), locally advanced pancreatic cancer or non-small-cell lung carcinoma (NSCLC).
Epistemonikos ID: 1237c2f3593fef333f7c2c21a31e345424f5969a
First added on: Jun 07, 2022